Denca designs control system for pharma facility
Project in Liverpool worth £500,000
The new plant is being built to meet demand for the pharmaceutical firm’s dialysis substitute, which frees patients from the need to be connected to a dialysis machine for 8 hours at a time, instead enabling blood to be cleaned from the convenience of a portable bag.
Denca, based in Widnes, Cheshire has used its expertise to develop process diagrams, design and manufacture control panels, as well as provide software, programming, installation and commissioning. In total, five Siemens S7300 PLCs will be networked with MP 277 touchscreen HMIs, a Profibus Remote IO and communication.
John Talbot, sales and marketing director at Denca, said: ‘It’s not often in our line of work that you are given the opportunity to help, in however small a way, to improve lives. In this case, it’s hugely rewarding to know that, through the implementation of control systems for this groundbreaking new product, we would ultimately be helping the company to provide patients with a better control system to make their day to day lives a little easier.’
Denca works across a spectrum of industry sectors including automotive, chemical, food and beverage, healthcare and utilities. It provides process control solutions based on custom-designed, fully integrated PLC and HMI software for both mechanical and electrical operations as well as UKAS-traceable calibration and certification services.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Key drivers behind the rise of microsphere drug delivery systems
Microspheres shift drug delivery from broad distribution to precise targeting. These systems improve therapeutic consistency, lower systemic exposure, and adapt to complex treatment regimens. Their growth reflects progress in polymer science, pharmacokinetics, and the push for more individualised care in clinical settings. Let’s explore some of the key drivers behind the rise of microsphere drug delivery systems and look ahead to predict future growth trends
Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035